NTHI · Neonc Technologies Holdings, Inc.
$4.69
+0.09 (+1.85%)
At close · Aug 28
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the proceeds from the PIPE Financing and the Series A Convertible Preferred Stock financing have provided additional liquidity during the six months ended June 30, 2026, management does not believe these proceeds, together with the Company’s other available resources, are sufficient to fund operations for at least twelve months from the date of issuance of these financial statements, and substantial doubt about the Company’s ability to continue as a going concern therefore remains, as discussed above.”View the 10-Q filed Aug 10, 2026
Market Cap
$121.64M
Shares
25.94M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$39.99K
-51.8%
FY2025
Net Income
-$62.15M
-422.3%
FY2025
Operating Margin
-145637.52%
-137032.1pp
FY2025
Diluted EPS
-$3.20
-363.8%
FY2025
Operating Cash Flow
-$20.36M
-383.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| — | $39.99K | $83K | |
| $5.9M | $3.64M | $3.05M | |
| $4.37M | $4.82M | $1.68M | |
| $41.76M | $58.28M | $7.23M | |
| -$41.76M | -$58.24M | -$7.14M | |
| — | -145637.52% | -8605.45% | |
| $3.36M | $2.5M | $2.56M | |
| -$47.2M | -$62.15M | -$11.9M | |
| — | -155404.38% | -14335.5% | |
| USD/shares | -$2.08 | -$3.20 | -$0.69 |
| USD/shares | -$2.08 | -$3.20 | -$0.69 |
| shares | — | 19.4M | 17.34M |
| shares | — | 22M | 17.34M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.76×
EV/EBIT
—
Peer median 8.81×
P/E (TTM)
—
Peer median 9.58×
Peer medians compare against the 299 similar-size Biotechnology companies (of 524 listed).
Key facts
CIK
1979414
CUSIP
64051A101
13F (30d)
18 filings
18 filers
Visit website
Investor relations